Vaccine Fund resource mobilization level of $400 million/year achieved by end of 2006 (interim 2005 milestone for this effort is roughly $325 million/yr)

Map | A Partnership for Children's Health Search: | Advanced Search

Home General Information Country Support Board Task Forces Resources Media Center

About the alliance The Vaccine Fund Immunization information

Work plan Background FAQ Governance Contact us

Printer-friendly format


		Quick Reference: What is GAVI? GAVI Fact Sheets Governance Board Documents Guidelines & Forms Press Releases Immunization Information Immunization Focus Latest Issue GAVI Update

Securing long-term financing =>> Recapitalization of The Vaccine Fund =>>

Vaccine Fund resource mobilization level of $400 million/year achieved by end of 2006 (interim 2005 milestone for this effort is roughly $325 million/yr)

Responsible entity: The Vaccine Fund
Completed by: December 2005
Total budget: $0

Target description and how it will help reach GAVI milestones

Allows for GAVI partners to meet current commitments, including assuring sufficient supply of vaccines are available to meet national needs at a reasonable price using innovative vaccine procurement agreements. Achievement of the target will be crucial to the long term credibility and future viability of GAVI and the Vaccine Fund.

ALL MILESTONES: Alliance fundraising goals will not be met unless VF/GAVI secretariat led fund-raising efforts are closely aligned with the GAVI strategic planning process, recognize the needs of the partners and are based on well considered plans that clearly delineate the roles and responsibilities of each of the partners.

Justification for selection of activities

Establishing a consistent fundraising base can only be accomplished if efforts are based on a well considered fund raising strategy that fully captures the capabilities of the all the partners, and has sufficient human resources for its implementation.

The ambitious fundraising targets will only be met if:

they are based on rigorous analyses of commitments to date,
success to date is effectively communicated,
future resources mobilization plans are integrally aligned with Alliance priorities which resonate both nationally and globally,
the effort efficiently harnesses and integrates the capabilities of all of the GAVI partners, and
plans effectively use all of the attributes of the alliance in an innovative fashion.

Opportunities to capitalize use of the Vaccine Fund balance sheet attribute will be crucial to the long term credibility and future viability of GAVI and the Vaccine Fund. Opportunities currently being explored include

new vaccine procurement agreements (including multi-year guaranteed agreements),
creative means for stimulating vaccine development and introduction and
innovative new instruments that can be used to finance immunization programs such as IDA buy downs.

ACTION PLAN

Activities	Budget	Coordinating partner/ support partners	Expected outcomes
Cost estimates for VF commitments	$0	VF WHO Secretariat UNICEF	• Cost estimates for current GAVI/Vaccine Fund commitments and "partners' best estimate" of uptake.
Realignment and expansion of VF capacities	$0	VF Secretariat	Fully staffed resource mobilization team at the VF, including • the development of VF Nominations and Development committees, • an internal Board Building Group, • launch of International Advisory Council, and • identification of national champions in priority countries.
Resource mobilization efforts closely aligned	$0	VF Secretariat UNICEF WHO BMGF	• Resource Mobilization Team working in close alliance with GAVI Secretariat on government outreach and communications. • Joint annual progress report, • joined-up communications strategy developed, • partnership established for selected countries to serve as basis for donor reporting. • This effort will recognize the dual role of partners to fund raise for agency
Implement "Grand Campaign"	included in VF budget	VF Secretariat GAVI Partners	• Development and implementation of GAVI/VF “The Grand Campaign for Child Immunization” targeting a. governments ($190 million/yr), b. US Private sector ($55 million/yr), c. European private sector ($15 million/yr), d. EU ($ 40 million/yr), e. Pharmaceutical industry ($15 million/yr) - all by end 2006.